Post-Traumatic Stress Disorder (PTSD) Trends and Forecast
The future of the global post-traumatic stress disorder (PTSD) market looks promising with opportunities in the hospital and clinic markets. The global post-traumatic stress disorder (PTSD) market is expected to reach an estimated $1.4 billion by 2030 with a CAGR of 4.6% from 2024 to 2030. The major drivers for this market are increasing prevalence of post-traumatic stress disorders, rising awareness towards mental health issues, and growing demand of mental health services along with surhing R&D activities for treatment of post-traumatic stress disorders.A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.
Post-Traumatic Stress Disorder (PTSD) by Segment
The study includes a forecast for the global post-traumatic stress disorder (PTSD) by product type, age group, end use, and region.Post-Traumatic Stress Disorder (PTSD) Market by Product Type [Shipment Analysis by Value from 2018 to 2030]:
- Antidepressants
- Cognitive Therapy
- Anti-Anxiety Drugs
- Exposure Therapy
- Eye Movement Desensitization & Reprocessing (EMDR)
- PSTD Therapeutics
Post-Traumatic Stress Disorder (PTSD) Market by Age Group [Shipment Analysis by Value from 2018 to 2030]:
- Children
- Adult
Post-Traumatic Stress Disorder (PTSD) Market by End Use [Shipment Analysis by Value from 2018 to 2030]:
- Hospitals
- Clinics
Post-Traumatic Stress Disorder (PTSD) Market by Region [Shipment Analysis by Value from 2018 to 2030]:
- North America
- Europe
- Asia Pacific
- The Rest of the World
List of Post-Traumatic Stress Disorder (PTSD) Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies post-traumatic stress disorder (PTSD) companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the post-traumatic stress disorder (PTSD) companies profiled in this report include-- Glaxosmithkline
- Pfizer
- Eli Lilly & Company
- Azevan Pharmaceuticals
- Otsuka Pharmaceutical
- Astrazeneca
- Neurocrine Biosciences
- Nuvo Pharmaceuticals
- Marinus Pharmaceuticals
- Tonix Pharmaceuticals
Post-Traumatic Stress Disorder (PTSD) Market Insights
The publisher forecasts that adult will remain the larger semgent over the forecast period due to large number of patients in this age group, growing mental health disorder cases in the adult group, and rising traumatic experiences.Within this market, hospitals will remain the larger segment due to their importance in primary healthcare settings for the diagnosis and treatment of post-traumatic stress disorder cases along with their capabilities to manage acute crisis.
North America will remain the largest region due to increasing prevalence of post-traumatic stress disorder and growing demand of mental healthcare services in the region.
Features of the Global Post-Traumatic Stress Disorder (PTSD) Market
- Market Size Estimates: Post-traumatic stress disorder (PTSD) market size estimation in terms of value ($B).
- Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.
- Segmentation Analysis: Post-traumatic stress disorder (PTSD) market size by product type, age group, end use, and region in terms of value ($B).
- Regional Analysis: Post-traumatic stress disorder (PTSD) market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
- Growth Opportunities: Analysis of growth opportunities in different product types, age groups, end uses, and regions for the post-traumatic stress disorder (PTSD) market.
- Strategic Analysis: This includes M&A, new product development, and competitive landscape of the post-traumatic stress disorder (PTSD) market.
- Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
FAQ
Q.1 What is the post-traumatic stress disorder (PTSD) market size?Answer: The global post-traumatic stress disorder (PTSD) market is expected to reach an estimated $1.4 billion by 2030.
Q.2 What is the growth forecast for post-traumatic stress disorder (PTSD) market?
Answer: The global post-traumatic stress disorder (PTSD) market is expected to grow with a CAGR of 4.6% from 2024 to 2030.
Q.3 What are the major drivers influencing the growth of the post-traumatic stress disorder (PTSD) market?
Answer: The major drivers for this market are increasing prevalence of post-traumatic stress disorders, rising awareness towards mental health issues, and growing demand of mental health services along with surhing R&D activities for treatment of post-traumatic stress disorders.
Q4. What are the major segments for post-traumatic stress disorder (PTSD) market?
Answer: The future of the post-traumatic stress disorder (PTSD) market looks promising with opportunities in the hospital and clinic markets.
Q5. Who are the key post-traumatic stress disorder (PTSD) market companies?
Answer: Some of the key post-traumatic stress disorder (PTSD) companies are as follows:
- Glaxosmithkline
- Pfizer
- Eli Lilly & Company
- Azevan Pharmaceuticals
- Otsuka Pharmaceutical
- Astrazeneca
- Neurocrine Biosciences
- Nuvo Pharmaceuticals
- Marinus Pharmaceuticals
- Tonix Pharmaceuticals
Answer: The publisher forecasts that adult will remain the larger semgent over the forecast period due to large number of patients in this age group, growing mental health disorder cases in the adult group, and rising traumatic experiences.
Q7. In post-traumatic stress disorder (PTSD) market, which region is expected to be the largest in next 5 years?
Answer: North America will remain the largest region due to increasing prevalence of post-traumatic stress disorder and growing demand of mental healthcare services in the region.
Q.8 Do we receive customization in this report?
Answer: Yes, the publisher provides 10% customization without any additional cost.
This report answers following 11 key questions:
Q.1. What are some of the most promising, high-growth opportunities for the post-traumatic stress disorder (PTSD) market by product type (antidepressants, cognitive therapy, anti-anxiety drugs, exposure therapy, eye movement desensitization & reprocessing (EMDR), and PSTD therapeutics), age group (children and adult), end use (hospitals and clinics), and region (North America, Europe, Asia Pacific, and the Rest of the World)?Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Global Post-Traumatic Stress Disorder (PTSD) Market : Market Dynamics
3. Market Trends and Forecast Analysis from 2018 to 2030
4. Market Trends and Forecast Analysis by Region from 2018 to 2030
5. Competitor Analysis
6. Growth Opportunities and Strategic Analysis
7. Company Profiles of Leading Players
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Glaxosmithkline
- Pfizer
- Eli Lilly & Company
- Azevan Pharmaceuticals
- Otsuka Pharmaceutical
- Astrazeneca
- Neurocrine Biosciences
Methodology
The analyst has been in the business of market research and management consulting since 2000 and has published over 600 market intelligence reports in various markets/applications and served over 1,000 clients worldwide. Each study is a culmination of four months of full-time effort performed by the analyst team. The analysts used the following sources for the creation and completion of this valuable report:
- In-depth interviews of the major players in the market
- Detailed secondary research from competitors’ financial statements and published data
- Extensive searches of published works, market, and database information pertaining to industry news, company press releases, and customer intentions
- A compilation of the experiences, judgments, and insights of professionals, who have analyzed and tracked the market over the years.
Extensive research and interviews are conducted in the supply chain of the market to estimate market share, market size, trends, drivers, challenges and forecasts.
Thus, the analyst compiles vast amounts of data from numerous sources, validates the integrity of that data, and performs a comprehensive analysis. The analyst then organizes the data, its findings, and insights into a concise report designed to support the strategic decision-making process.
LOADING...
